Breast pain

par Bundred, Nigel J
Publié 2007

Do early premalignant changes in normal breast epithelial cells predict cancer development?

par Clarke, Robert B, Bundred, Nigel J
Publié 2005

Can preoperative factors predict for residual malignancy after breast biopsy for invasive cancer?: Authors' reply

par Bundred, Nigel J, Walls, Janet, Baildam, Andrew D
Publié 1996

Combined Inhibition of ErbB1/2 and Notch Receptors Effectively Targets Breast Ductal Carcinoma In Situ (DCIS) Stem/Progenitor Cell Activity Regardless of ErbB2 Status

par Farnie, Gillian, Willan, Pamela M., Clarke, Robert B., Bundred, Nigel J.
Publié 2013

Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)

par Farnie, Gillian, Johnson, Rachael L, Williams, Kathryn E, Clarke, Robert B, Bundred, Nigel J
Publié 2014

Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and...

par Wärnberg, Fredrik, White, Daniel, Anderson, Elizabeth, Knox, Fiona, Clarke, Robert B, Morris, Julie, Bundred, Nigel J
Publié 2006

Tissue Factor promotes breast cancer stem cell activity in vitro

par Shaker, Hudhaifah, Harrison, Hannah, Clarke, Robert, Landberg, Goran, Bundred, Nigel J., Versteeg, Henri H., Kirwan, Cliona C.
Publié dans Oncotarget (2016)

Randomized controlled trial of stereotactic 11-G vacuum-assisted core biopsy for the diagnosis and management of mammographic microcalcification

par Bundred, Sara M, Maxwell, Anthony J, Morris, Julie, Lim, Yit Y, Harake, MD Janick, Whiteside, Sigrid, Bundred, Nigel J
Publié dans Br J Radiol (2016)

Prognostic value of ER and PgR expression and the impact of multi-clonal expression for recurrence in ductal carcinoma in situ: Results from the UK/ANZ DCIS trial

par Thorat, Mangesh A., Levey, Pauline M., Jones, J. Louise, Pinder, Sarah E., Bundred, Nigel J., Fentiman, Ian S., Cuzick, Jack
Publié dans Clin Cancer Res (2021)

Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial

par Thorat, Mangesh A., Levey, Pauline M., Jones, J. Louise, Pinder, Sarah E., Bundred, Nigel J., Fentiman, Ian S., Cuzick, Jack
Publié dans Clin Cancer Res (2021)

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

par Foster, Fiona M, Owens, Thomas W, Tanianis-Hughes, Jolanta, Clarke, Robert B, Brennan, Keith, Bundred, Nigel J, Streuli, Charles H
Publié 2009

Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-dependent and -independent Mechanisms

par Singh, Jagdeep K., Farnie, Gillian, Bundred, Nigel J., Simões, Bruno M, Shergill, Amrita, Landberg, Göran, Howell, Sacha, Clarke, Robert B.
Publié dans Clin Cancer Res (2012)

Regulation of Breast Cancer Stem Cell Activity by Signalling Through the Notch4 Receptor

par Harrison, Hannah, Farnie, Gillian, Howell, Sacha J, Rock, Rebecca E, Stylianou, Spyros, Brennan, Keith R, Bundred, Nigel J, Clarke, Robert B
Publié 2010

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity

par Timbrell, Simon, Aglan, Hosam, Cramer, Angela, Foden, Phil, Weaver, David, Pachter, Jonathan, Kilgallon, Aoife, Clarke, Robert B., Farnie, Gillian, Bundred, Nigel J.
Publié dans NPJ Breast Cancer (2021)

Recruitment to the “Breast—Activity and Healthy Eating After Diagnosis” (B-AHEAD) Randomized Controlled Trial

par Pegington, Mary, Adams, Judith E., Bundred, Nigel J., Campbell, Anna M., Howell, Anthony, Howell, Sacha J., Speed, Shaun, Wolstenholme, Jane, Harvie, Michelle N.
Publié dans Integr Cancer Ther (2017)

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

par Cuzick, Jack, Sestak, Ivana, Pinder, Sarah E, Ellis, Ian O, Forsyth, Sharon, Bundred, Nigel J, Forbes, John F, Bishop, Hugh, Fentiman, Ian S, George, William D
Publié 2010

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study...

par Castle, John, Blower, Emma, Bundred, Nigel J., Harvey, James R., Thachil, Jecko, Marshall, Andrea, Cox, Karina, Cicconi, Silvia, Holcombe, Chris, Palmieri, Carlos, Kirwan, Cliona C.
Publié dans Trials (2020)

Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre‐invasive phenomena that is prognostic in invasion

par Shaker, Hudhaifah, Bundred, Nigel J., Landberg, Göran, Pritchard, Susan A., Albadry, Harith, Nicholson, Sarah L., Harries, Lauren J., Heah, Jing Y. E., Castle, John, Kirwan, Cliona C.
Publié dans Cancer Med (2020)

Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy

par Bundred, Nigel J, Kenemans, Peter, Yip, Cheng Har, Beckmann, Matthias W, Foidart, Jean-Michel, Sismondi, Piero, Schoultz, Bo von, Vassilopoulou-Sellin, Rena, Galta, Rachid El, Lieshout, Eugenie Van, Mol-Arts, Mirjam, Planellas, Juan, Kubista, Ernst
Publié 2012

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS):a randomised, multicentre, open-label, phase 3 non-inferiority tria...

par Donker, Mila, van Tienhoven, Geertjan, Straver, Marieke E, Meijnen, Philip, van de Velde, Cornelis J H, Mansel, Robert E, Cataliotti, Luigi, Westenberg, A Helen, Klinkenbijl, Jean H G, Orzalesi, Lorenzo, Bouma, Willem H, van der Mijle, Huub C J, Nieuwenhuijzen, Grard A P, Veltkamp, Sanne C, Slaets, Leen, Duez, Nicole J, de Graaf, Peter W, van Dalen, Thijs, Marinelli, Andreas, Rijna, Herman, Snoj, Marko, Bundred, Nigel J, Merkus, Jos W S, Belkacemi, Yazid, Petignat, Patrick, Schinagl, Dominic A X, Coens, Corneel, Messina, Carlo G M, Bogaerts, Jan, Rutgers, Emiel J T
Publié dans Lancet Oncol (2014)